Liver Disease Clinical Trials in Philadelphia

Showing 41-60 of 79 trials

Prehabilitation Intervention to Maximize Early Recovery (PRIMER) in Liver Transplantation

NCT03584646

This is a single center, 2-arm, patient-randomized study evaluating the feasibility and potential efficacy of the PRIMER intervention in improving physical function and reducing frailty in adult Liver Transplant candidates. The intervention will consist of a patient-tailored prehabilitation program designed to reduce frailty, improve physical function and nutritional status, and optimize pre- and post-transplant outcomes.

Liver DiseasesEnd Stage Liver DiseaseFrailty

University of Pennsylvania30 participantsStarted Feb 2018

Philadelphia, Pennsylvania, United States

COMPLETEDPhase 2< 1 mile

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis

NCT03486912

This is a study of experimental medication BMS-986036 given to adults with Nonalcoholic Steatohepatitis (NASH; the buildup of fat and inflammation in the liver that is not caused by alcohol) and liver cirrhosis (liver damage characterized by normal liver tissue being replaced by scar tissue).

Hepatic CirrhosisLiver FibrosisNonalcoholic Fatty Liver Disease (NAFLD)+1 more

Bristol-Myers Squibb155 participantsStarted Jun 2018

Madison, Alabama, United States • Chandler, Arizona, United States • Phoenix, Arizona, United States +88 more locations

Prehabilitation Intervention to Maximize Early Recovery (PRIMER) in Liver Transplantation

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis

Liver Disease Trials in Other Cities

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis

Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis

Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant

Validation of Point of Care Liver Function Tests

Monitoring of Symptoms and Cognitive Function Using Telehealth

Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH

A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH

Integrated Stepped Care for Unhealthy Alcohol Use in HIV

Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis

Losartan for the Treatment of Pediatric NAFLD

Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children

Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis

Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis

Assessing Portal Hypertension With Methacetin Breath Test

Non-invasive Methods and Surgical Risk Stratification in Cirrhotics Undergoing Elective Extrahepatic Surgery

A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.

Prediction Value of the BreathID 13C-Methacetin Breath Test for Hepatic Decompensation

Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function

Other Conditions in Philadelphia